Shots: Sierra will pay $3M upfront and ~$195M milestone payments to Gilead and additional royalties from mid-teen-to-high-twenties on net sales Sierra will continue all currently ongoing clinical studies with Momelotinib following a transition period Momelotinib (a JAK 1/2 and ACVR1 Inhibitor) is in Phase III, has being administered to ~1200 patients, since 2009, and is […]Read More
